This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheralarterydisease is essential to improve outcomes and reduce amputation risk, heartattack, stroke and death for people with PeripheralArteryDisease (PAD).
The Efemoral Vascular Scaffold System (EVSS) offers a new approach to treating peripheralarterial occlusive disease (PAOD) by addressing the specific anatomic challenges and complex biomechanics of patients with athero-occlusive disease in the leg. The global burden of peripheralarterydisease.
A study in the Journal of Vascular Surgery revealed that adding FFRCT assessments to patient workups prior to peripheralarterydisease surgeries has a massive impact on coronary arterydisease detection, treatments, and long-term outcomes.
The Shockwave E 8 catheter is designed to optimize the treatment of patients with calcified femoro-popliteal and below-the-knee peripheralarterydisease (PAD), including patients with complex chronic limb-threatening ischemia (CLTI). PAD affects more than eight million people aged 40 and older in the United States.
Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary arterydisease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
years of age, P <0.001), cerebral or peripheralarterydisease (6.2% There may be no better study to symbolize the dysfunction that has invaded cardiology than the VIRGO trial, a study examining the outcomes of young patients (18-55) presenting to the hospital with a heartattack. years of age versus 59.0±8.4
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content